Related Experiment Video

Updated: May 28, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Molecular aspects of renal cell carcinoma: a review

Hari Koul, Jung-Sik Huh, Kyle O Rove

    American Journal of Cancer Research
    |October 5, 2011
    PubMed

    Insights

    Renal cell carcinoma (RCC) is a growing cancer affecting kidney tubules. Advances in molecular markers are improving diagnosis and targeted therapies for this increasingly detected disease.

    Area of Science:

    • Oncology
    • Nephrology
    • Urology

    Background:

    • Renal cell carcinoma (RCC) incidence is rising annually, comprising 5% of adult epithelial cancers.
    • Clear cell carcinoma is the most common histological subtype of RCC.
    • RCC often lacks early symptoms, leading to incidental detection via imaging.

    Purpose of the Study:

    • To review current knowledge on renal cell carcinoma (RCC) epidemiology, pathophysiology, and clinical evaluation.
    • To discuss contemporary treatment strategies and future research directions for RCC.
    • To highlight the impact of new molecular markers and targeted therapies in RCC management.

    Main Methods:

    • A comprehensive literature review was conducted using PubMed.
    • The review focused on epidemiology, pathophysiology, evaluation, and treatment of RCC.
    • Discussions included novel subtypes and molecular-targeted therapies.

    Main Results:

    • RCC incidence is increasing, with incidental detection on the rise due to advanced imaging.
    • New molecular and cytogenetic markers have led to novel RCC subtype classifications.
    • Molecular-targeted therapy is now available for advanced-stage RCC.

    Conclusions:

    • Despite challenges in early diagnosis, recent molecular discoveries are transforming RCC understanding and treatment.
    • Continued research is vital for improving early detection and therapeutic outcomes in renal cell carcinoma.
    • The evolving landscape of RCC necessitates updated knowledge on its epidemiology, treatment, and emerging therapies.

    More Related Videos

    Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

    Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

    Published on: February 8, 2020

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

    Published on: April 12, 2017

    Related Concept Videos

    Metastasis02:30

    Metastasis

    Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
    Epithelial-to-Mesenchymal Transition
    The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
    Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
    Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...